This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Shkreli Arrest Won't Stop Drug Price Debate but Could Kill KaloBios

The charges brought against Martin Shkreli are not related at all to the drug-price gouging which made him a public villain and the target of politicians like Hillary Clinton.

AstraZeneca, Gilead Drug License Deals Could Pinch AbbVie Growth

AstraZeneca and Gilead Sciences announced separate deals Thursday that strengthen their respective cancer and inflammatory disease pipelines.

The Nominees for Best Biopharma CEO of 2015 Are...

One of these biopharma executives, or the grouped nominees, will win the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO. Here are the best biopharma CEOs.

Akebia Secures Asian Partner and Funding for Anemia Pill

Mitsubishi will pay Akebia $40 million upfront to license vadadustat for the Asian market. The Japanese drug maker will also contribute another $60 million towards Akebia'a global phase III program.

Investors Remain Skeptical about Bluebird Gene Therapy for Blood Disease

Bluebird Bio is going to have a rough Monday because of the disappointing gene therapy data presented over the weekend at the American Society of Hematology annual meeting.

Global Blood Bolsters Sickle Cell Drug With More Patient Data

Expanded results from a Global Blood study continue to show encouraging reductions in the number of sickled red blood cells, supported by other improvements in measures of the disease.

Bluebird Sickle Cell Gene Therapy Falls Short of High Expectations

Bluebird's challenge is to understand why exemplary results seen in a single French sickle cell patient are not being duplicated in the three other sickle cell patients treated more recently.

Bellicum Therapy Reduces Risk from Mismatched Stem Cell Transplants

Modified donor T cells and a molecular "safety switch" developed by Bellicum Pharmaceuticals improved the safety and outcome of stem cell transplants performed on children suffering from rare blood diseases.

Bluebird, Celgene See Promise in T Cell Therapy for Multiple Myeloma

U.S. researchers using a personalized therapy made from genetically engineered T cells induced remissions in some patients with highly advanced multiple myeloma, a type of blood cancer affecting plasma cells.

Zafgen Obesity Drug Marred by Second Patient Death

Zafgen shares plunge on concerns regulators could step in to halt clinical development of the company's obesity drug for patient-safety reasons.

Page 4 of 351
Top Rated Stocks Top Rated Funds Top Rated ETFs